BCM
TOVX icon

Bayesian Capital Management’s Theriva Biologics TOVX Stock Holding History

Bayesian Capital Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2
Closed -$31K – 504
2016
Q2 		$31K Buy
+2
New +$37.6K 0.02% 382

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bayesian Capital Management's TOVX Position: Q3 2016 in Review

Bayesian Capital Management sold out of Theriva Biologics (TOVX) in Q3 2016, closing a stake of 2 shares — an estimated $31K sold.

Bayesian Capital Management first reported a position in TOVX in Q2 2016 and held it in 1 quarter. The position peaked at $31K in Q2 2016. 60 funds tracked by Wall St. Rank hold TOVX as of Q3 2016.

  • Bayesian Capital Management reported no remaining Theriva Biologics position as of Q3 2016 after selling out during the quarter.
  • Bayesian Capital Management sold 2 Theriva Biologics shares in Q3 2016, an estimated $31K.
  • Bayesian Capital Management first reported a position in Theriva Biologics in Q2 2016 and held it in 1 quarter.
  • Bayesian Capital Management's Theriva Biologics position peaked at $31K in Q2 2016.
  • 60 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2016.

Based on Bayesian Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.